Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acimtamig + AlloNK in R/R Hodgkin Lymphoma and PTCL
NCT05883449Phase 2Terminated
- Sponsor
- Affimed
- Start
- Oct 2023
- Primary completion
- Nov 2024
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of acimtamig, Natural killer cell infusion in Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), sponsored by Affimed. Started Oct 2023; status: terminated.
02
Drugs
acimtamigNatural killer cell infusion
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05883449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883449.